[1]陈 娟,朱凤婷,冯冬婵,等.清胰化积汤联合介入化疗栓塞治疗晚期胰腺癌临床研究[J].陕西中医,2023,(2):178-182.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.009]
　CHEN Juan,ZHU Fengting,FENG Dongchan,et al.Efficacy of Qingyi Huaji decoction combined with interventional chemoembolization in the treatment of advanced pancreatic cancer[J].,2023,(2):178-182.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.009]
点击复制

清胰化积汤联合介入化疗栓塞治疗晚期胰腺癌临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年2期
页码:
178-182
栏目:
临床研究
出版日期:
2023-02-05

文章信息/Info

Title:
Efficacy of Qingyi Huaji decoction combined with interventional chemoembolization in the treatment of advanced pancreatic cancer
作者:
陈 娟; 朱凤婷; 冯冬婵; 麦丽珍
(海南省中医院,海南 海口 570203)
Author(s):
CHEN Juan; ZHU Fengting;  FENG Dongchan; MAI Lizhen
(Hainan Hospital of Traditional Chinese Medicine,Haikou 570203,China)
关键词:
胰腺癌;  清胰化积汤;  介入化疗栓塞;  免疫抑制酸性蛋白;  碱性纤维母细胞生长因子;  可溶性肿瘤坏死因子受体Ⅰ
Keywords:
Pancreatic cancer;  Qingyi Huaji decoction;  Interventional chemoembolization;  Immunosuppressive acidic protein;  Basic fibroblast growth factor;  Soluble tumor necrosis factor receptor Ⅰ
分类号:
R 735.9
DOI:
DOI:10.3969/j.issn.1000-7369.2023.02.009
文献标志码:
A
摘要:
目的:探讨清胰化积汤联合介入化疗栓塞治疗晚期胰腺癌的疗效及对患者血清免疫抑制酸性蛋白(IAP)、碱性纤维母细胞生长因子(bFGF)及可溶性肿瘤坏死因子受体Ⅰ(sTNFRⅠ)的影响。方法:92例晚期胰腺癌患者,以随机数字表法分为研究组和对照组,各46例。对照组接受介入化疗栓塞,研究组在对照组的基础上接受清胰化积汤治疗,两组治疗时间均为8周。对比两组中医症候积分、糖类抗原199(CA199)、癌胚抗原(CEA)、自然杀伤T细胞(NKT)、IAP、bFGF、sTNFRⅠ、卡氏功能状态(KPS)评分、生活质量评分表(QOL)、不良反应及临床疗效,记录两组生存情况。结果:治疗后两组中医症候积分均降低,研究组降低更明显(P<0.05)。治疗后两组CA199、CEA均降低,且研究组更低(P<0.05); 治疗后两组NKT均升高,研究组升高更明显(P<0.05); 治疗后两组IAP、bFGF、sTNFRⅠ均降低,且研究组更低(P<0.05)。治疗后两组KPS评分、QOL评分均升高,且研究组更高(P<0.05); 两组Ⅰ-Ⅳ级肝肾功能损害、胃肠道反应、骨髓抑制发生率比较差异无统计学意义(P>0.05)。研究组生存率高于对照组(P<0.05); 研究组总有效率较对照组高(P<0.05)。结论:清胰化积汤联合介入化疗栓塞治疗晚期胰腺癌可改善患者临床症状、肿瘤标志物水平与免疫功能,提高患者生活质量,且安全性与预后良好。
Abstract:
Objective:To investigate the efficacy of Qingyi Huaji decoction combined with interventional chemoembolization in the treatment of advanced pancreatic cancer and its effects on serum immunosuppressive acidic protein(IAP),basic fibroblast growth factor(bFGF)and soluble tumor necrosis factor receptor Ⅰ(sTNFRⅠ).Methods:92 patients with advanced pancreatic cancer were randomly divided into study group(46 cases)and control group(46 cases).The control group received interventional chemoembolization,and the study group received Qingyi Huaji decoction on the basis of the control group.The treatment time of both groups was 8 weeks.Two groups of TCM symptom scores,carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA),natural killer T cells(NKT),IAP,bFGF,sTNFRⅠ,Karnofsky functional status(KPS)score,quality of life score table(QOL),adverse reactions and clinical efficacy were compared.After 3 years of follow-up,the survival of the two groups was recorded.Results:After treatment,TCM symptom scores in both groups were decreased,and the research group was lower(P<0.05).After treatment,CA199 and CEA in the two groups were decreased,and lower in the study group(P<0.05).After treatment,NKT increased was higher in the study group(P<0.05).After treatment,IAP,bFGF and sTNFRⅠ in the two groups were decreased,and lower in the study group(P<0.05).After treatment,the KPS score and QOL score of the two groups were increased,and the research group was higher(P<0.05).There was no difference in the incidence of Ⅰ-Ⅳ class liver and kidney function damage,gastrointestinal tract reaction and bone marrow suppression between the two groups(P>0.05).The survival rate of the study group was higher than that of the control group(P<0.05).The total effective rate in the study group was higher than that in the control group(P<0.05).Conclusion:Qingyi Huaji decoction combined with interventional chemoembolization has a definite curative effect in the treatment of advanced pancreatic cancer,and can improve the clinical symptoms,tumor marker levels and immune status of patients,improve the quality of life of patients,and has good safety and prognosis.

参考文献/References:

[1] 朱鑫哲,李 浩,徐华祥,等.2021年胰腺癌研究及诊疗新进展[J].中国癌症杂志,2022,32(1):1-12.
[2] 刘心悦,巫燕芬,马子骞,等.胰腺癌患者临床特征及预后分析[J].河北医药,2020,42(11):1615-1619.
[3] Zeng S,Pottler M,Lan B,et al.Chemoresistance in pancreatic cancer[J].Int J Mol Sci,2019,20(18):4504.
[4] 燕 婧,冯 芸,李 丹,等.microRNA-185-5p真核表达载体构建及其对胰腺癌Panc-1细胞增殖的影响[J].陕西医学杂志,2021,50(11):1323-1326,1332.
[5] 杨 双,王春微,刘海军,等.护胃汤配合西药预防Ⅲ期胰腺癌放疗后消化道黏膜放射性损伤临床研究[J].陕西中医,2022,43(5):600-603.
[6] 韩 俊,谢安卫,刘利红.清胰化积汤联合动脉灌注化疗治疗中晚期胰腺癌[J].中医学报,2018,33(7):1165-1169.
[7] Hong SW,Shin JS,Moon JH,et al.Chemosensitivity to HM90822,a novel synthetic IAP antagonist,is determined by p-Akt-inducible XIAP phosphorylation in human pancreatic cancer cells[J].Invest New Drugs,2020,38(6):1696-1706.
[8] Mizuta M,Shimizu M,Irabu H,et al.Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children[J].Rheumatology(Oxford),2021,60(1):231-238.
[9] Wu H,Ma S,Xiang M,et al.HTRA1 promotes transdifferentiation of normal fibroblasts to cancer-associated fibroblasts through activation of the NF-κB/bFGF signaling pathway in gastric cancer[J].Biochem Biophys Res Commun,2019,514(3):933-939.
[10] 中国抗癌协会胰腺癌专业委员会.胰腺癌综合诊治指南(2018版)[J].中华外科杂志,2018,56(7):481-494.
[11] 中华人民共和国卫生部.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版,2002:77-85.
[12] Khalid MA,Achakzai IK,Ahmed KS,et al.The use of Karnofsky Performance Status(KPS)as a predictor of 3 month post discharge mortality in cirrhotic patients[J].Gastroenterol Hepatol Bed Bench,2018,11(4):301-305.
[13] Park T,Hirani S.A methodological review of quality of life scales used in schizophrenia[J].J Nurs Meas,2021,29(1):34-52.
[14] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[15] 石元凯,孙 燕.临床肿瘤内科手册[M].6版.北京:人民卫生出版社,2015:159-160.
[16] 张云云,巩想平.埃索美拉唑联合奥曲肽、生长抑素治疗重症胰腺炎疗效及对患者血乳酸水平、肠道黏膜屏障功能的影响[J].陕西医学杂志,2021,50(11):1420-1422,1426.
[17] 童向斌,马 君,胡期伟.替吉奥联合扶正消积汤治疗晚期胰腺癌的临床疗效观察[J].浙江医学,2021,43(6):669-671.
[18] 蒋 洁,任加强,王 铮,等.苦参素通过sHH信号通路抑制胰腺癌细胞增殖和侵袭能力研究[J].陕西中医,2021,42(11):1499-1503.
[19] 郭延玲,胡彦辉.清胰化积方联合顺铂治疗胰腺癌疗效及对TGF-β/smads信号通路的影响[J].陕西中医,2018,39(9):1210-1213.
[20] 许卫娜,王 婷.患者血清CEA、CA724、CA199水平对胰腺癌的评估价值[J].实用癌症杂志,2019,34(5):747-749.
[21] 冯晓飞,周禄荣,金 迎,等.膈下逐瘀汤联合吉西他滨对胰腺癌患者细胞免疫功能、血清CEA、CA199、NKT的影响[J].中医药导报,2019,25(6):53-56.
[22] 王挺帅,张荣臻,王明刚,等.基于网络药理学及生物信息学探讨大黄促进肝再生的机制研究[J].时珍国医国药,2020,31(6):1297-1301.
[23] 刘 毅,王瑞敏,彭雪峰,等.基于数据挖掘、网络药理学及临床观察探究贾跃进治疗女性失眠症用药规律及机制[J].中草药,2021,52(15):4626-4640.

相似文献/References:

[1]肖雅瑜,曾普华△,郜文辉,等.曾普华教授辨治胰腺癌特色探析*[J].陕西中医,2020,(5):667.[doi:DOI:10.3969/j.issn.10007369.2020.05.032]
　XIAO Yayu,ZENG Puhua,GAO Wenhui,et al.Analysis on the characteristics of professor Zeng Puhua's treatment of pancreatic cancer based on syndrome differentiation[J].,2020,(2):667.[doi:DOI:10.3969/j.issn.10007369.2020.05.032]
[2]蒋 洁,任加强,王 铮,等.苦参素通过sHH信号通路抑制胰腺癌细胞增殖和侵袭能力研究[J].陕西中医,2021,(11):1499.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.002]
　JIANG Jie,REN Jiaqiang,WANG Zheng,et al.The inhibition effect of matrine on the proliferation and invasion ability in pancreatic cancer cells via sHH signaling pathway[J].,2021,(2):1499.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.002]
[3]袁文婷,肖茂良,肖 锋.半枝莲提取物通过PI3K-Akt信号通路抑制胰腺癌模型大鼠肿瘤生长的机制研究[J].陕西中医,2021,(12):1676.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.005]
　YUAN Wenting,XIAO Maoliang,XIAO Feng.Mechanism of scutellaria barbata extract inhibiting tumor growth through PI3K-Akt signaling pathway in pancreatic cancer model rats[J].,2021,(2):1676.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.005]
[4]杨 双,王春微,刘海军,等.护胃汤配合西药预防Ⅲ期胰腺癌放疗后消化道黏膜放射性损伤临床研究[J].陕西中医,2022,(5):600.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.013]
　YANG Shuang,WANG Chunwei,LIU Haijun,et al.Huwei decoction combined with western medicine in preventing radiation injury of digestive tract mucosa in patients with Ⅲ stage pancreatic cancer after radiotherapy[J].,2022,(2):600.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.013]
[5]邢 莹,滕钰浩,王瑞平.王瑞平辨治胰腺癌经验探讨[J].陕西中医,2023,(2):241.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.024]
　XING Ying,TENG Yuhao,WANG Ruiping.Discussion on the experience of WANG Ruiping in syndrome differentiation and treatment of pancreatic cancer[J].,2023,(2):241.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.024]

备注/Memo

备注/Memo:
基金项目:海南省卫生健康行业科研项目(20A200516)
更新日期/Last Update: 2023-02-08